Brief: KemPharm announces licensing agreement with Acura

Acura Pharmaceuticals

18/10/2016 11:30

Oct 18 (Reuters) - KemPharm Inc  KMPH.O  -  
    * KemPharm announces licensing agreement with Acura 
Pharmaceuticals for aversion  abuse-deterrent technology 
    * Says agreement provided for an upfront cash payment of 
$3.5 million to Acura at execution 
    * Agreement provided for an upfront cash payment of $3.5 
million to Acura at execution 
    * Kempharm will solely own intellectual property resulting 
from any new product development 
    * Acura is eligible to receive royalty at low single-digit 
rate based on commercial sales by Co of all products developed 
under agreement 
    * Additional payments are provided in agreement should 
KemPharm exercise its option to use Acura's aversion technology 
with more than three products 
    * Agreement also grants KemPharm development and 
commercialization rights for up to three IR product candidates 
containing two of KemPharm's opioid prodrugs 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nGNXNJSNYa 
Further company coverage:  KMPH.O  
 
 ((Bangalore.newsroom@thomsonreuters.com))